Clinical Trials

Carcinoma, Renal Cell

NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

BreastEndocrineGynecologicHead & NeckSarcoma

30 enrolled

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03527108 2026-05-22

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

36 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03646461 2026-05-22

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Phase 2 Terminated

5 enrolled 9 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

38 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT04503694 2026-05-22

REGINA

72 enrolled

Rectal Neoplasms

NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

EndocrineGenitourinaryNET

111 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT05498792 2026-05-22

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Phase EARLY_PHASE1 Recruiting

12 enrolled

Melanoma

NCT06812858 2026-05-22

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

83 enrolled

Hodgkin Disease

NCT06963905 2026-05-22

SIMONE

Phase 1/2 Recruiting

60 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07355205 2026-05-22

FLINN

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07603856 2026-05-22

REVIVE

39 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02696993 2026-05-20

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

80 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04015778 2026-05-20

A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

316 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04123379 2026-05-20

Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

48 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT06053658 2026-05-20

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

48 enrolled

Carcinoma, Renal Cell

NCT07013565 2026-05-20

ACCELERATE

20 enrolled

Lymphoma, Large-Cell, Anaplastic

NCT07551583 2026-05-20

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

15 enrolled

Hodgkin Disease

NCT05779423 2026-05-19

Cryoablation+Ipilimumab+Nivolumab in Melanoma

37 enrolled

Melanoma, Skin Neoplasms

NCT04984733 2026-05-18

ELEVATE

13 enrolled

Esophageal Neoplasms, Neoplasms

NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

36 enrolled

Phase EARLY_PHASE1 Enrolling by invitation

Melanoma

NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

18 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT06365619 2026-05-18

NeoRelapse

25 enrolled

Melanoma

NCT06712927 2026-05-18

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

60 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06863311 2026-05-18

EXACT

70 enrolled

Carcinoma, Renal Cell

NCT02693535 2026-05-15

TAPUR

MyeloidOther hematologic neoplasm

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03600155 2026-05-15

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1 Completed

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04019964 2026-05-15

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

8 enrolled 12 charts

Prostatic Neoplasms

NCT05704647 2026-05-15

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

30 enrolled

Melanoma

NCT06015724 2026-05-15

DARANIVOVAX

54 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04003649 2026-05-14

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

20 enrolled

CNS

Glioblastoma

NCT04042753 2026-05-14

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

9 enrolled

Endocrine

Pituitary Diseases, Pituitary Neoplasms

NCT04848116 2026-05-14

Spark2

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03033446 2026-05-13

Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

40 enrolled

Carcinoma, Hepatocellular

NCT01703949 2026-05-12

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

28 enrolled 11 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT04205409 2026-05-12

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

LymphoidOther hematologic neoplasmPlasma cell

20 enrolled 12 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03767582 2026-05-11

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Phase 1/2 Completed

22 enrolled 18 charts

Pancreatic Neoplasms

NCT04464759 2026-05-11

LIMIT

Phase 1/2 Recruiting

94 enrolled

Melanoma

NCT07128680 2026-05-11

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

33 enrolled

Phase EARLY_PHASE1 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07210632 2026-05-11

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

38 enrolled

CNS

Brain Neoplasms, Glioma

NCT03637543 2026-05-08

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

29 enrolled 13 charts

Prostatic Neoplasms

NCT05677490 2026-05-08

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Phase 3 Recruiting

382 enrolled

Adenocarcinoma Of Esophagus

NCT05723055 2026-05-08

NAHL

9 enrolled

Hodgkin Disease

NCT06632327 2026-05-08

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

1,100 enrolled

Lung Neoplasms

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

50 enrolled

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT03143270 2026-05-07

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

Phase EARLY_PHASE1 Active not recruiting

20 enrolled

Liver Neoplasms

NCT03927105 2026-05-07

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

4 enrolled 15 charts

Lymphoma, T-Cell, Peripheral

NCT03122522 2026-05-06

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

70 enrolled

Melanoma

NCT03355560 2026-05-06

Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy